AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure to Protect and Possible Enhancement of Challenge Infection by Four Cell-based Vaccines Prepared with Autologous Lymphoblasts
Overview
Authors
Affiliations
Immunogenicity and protective activity of four cell-based feline immunodeficiency virus (FIV) vaccines prepared with autologous lymphoblasts were investigated. One vaccine was composed of FIV-infected cells that were paraformaldehyde fixed at the peak of viral expression. The other vaccines were attempts to maximize the expression of protective epitopes that might become exposed as a result of virion binding to cells and essentially consisted of cells mildly fixed after saturation of their surface with adsorbed, internally inactivated FIV particles. The levels of FIV-specific lymphoproliferation exhibited by the vaccinees were comparable to the ones previously observed in vaccine-protected cats, but antibodies were largely directed to cell-derived constituents rather than to truly viral epitopes and had very poor FIV-neutralizing activity. Moreover, under one condition of testing, some vaccine sera enhanced FIV replication in vitro. As a further limit, the vaccines proved inefficient at priming animals for anamnestic immune responses. Two months after completion of primary immunization, the animals were challenged with a low dose of homologous ex vivo FIV. Collectively, 8 of 20 vaccinees developed infection versus one of nine animals mock immunized with fixed uninfected autologous lymphoblasts. After a boosting and rechallenge with a higher virus dose, all remaining animals became infected, thus confirming their lack of protection.
Bigay J, Le Grand R, Martinon F, Maisonnasse P Front Microbiol. 2022; 13:932408.
PMID: 36033843 PMC: 9399815. DOI: 10.3389/fmicb.2022.932408.
Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety.
Kostoff R, Kanduc D, Porter A, Shoenfeld Y, Calina D, Briggs M Toxicol Rep. 2020; 7:1448-1458.
PMID: 33110761 PMC: 7581376. DOI: 10.1016/j.toxrep.2020.10.016.
Miller C, Emanuelli M, Fink E, Musselman E, Mackie R, Troyer R NPJ Vaccines. 2018; 3:16.
PMID: 29736270 PMC: 5928050. DOI: 10.1038/s41541-018-0051-y.
Applications of the FIV Model to Study HIV Pathogenesis.
Miller C, Abdo Z, Ericsson A, Elder J, VandeWoude S Viruses. 2018; 10(4).
PMID: 29677122 PMC: 5923500. DOI: 10.3390/v10040206.
Hosie M, Techakriengkrai N, Beczkowski P, Harris M, Logan N, Willett B Vet Sci. 2017; 4(1).
PMID: 29056666 PMC: 5606627. DOI: 10.3390/vetsci4010007.